Skip to main content

Table 2 Univariate and multivariate analyses of overall survival (n = 36 HLA-A*2402-matched patients)

From: Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer

Variables   Univariate analysis Multivariate analysis
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Age ≥65 2.150 1.058 to 4.396 0.0345 1.691 0.798 to 3.588 0.1689
Gender male/female 1.193 0.581 to 2.436 0.6271    
Stage III/IV and Recurrence 0.743 0.275 to 1704 0.5033    
Hb ≥13.2 0.724 0.350 to 1.515 0.3859    
NLR ≥2.48 1.514 0.756 to 3.018 0.2384    
CEA ≥5.3 1.791 0.879 to 3.813 0.1095    
CA19-9 ≥541 1.853 0.862 to 3.935 0.1120    
IL-6 ≥0.97 0.906 0.454 to 1.851 0.7816    
PD-1+ CD4+ ≥1.83 2.962 1.383 to 6.471 0.0054 2.546 1.138 to 5.765 0.0231
Tim-3+ CD4+ ≥2.54 0.741 0.362 to 1.522 0.4091    
PD-1+ CD8+ ≥4.73 1.892 0.925 to 3.932 0.0803    
Tim-3+ CD8+ ≥4.58 0.881 0.429 to 1.799 0.7269    
Treg ≥1.93 0.880 0.420 to 1.794 0.7268    
MDSC ≥15.07 1.267 0.638 to 2.555 0.4981    
  1. Statistical significant results are highlighted in bold letters
  2. Abbreviations: HLA human leukocyte antigen, CI confidence interval, Hb hemoglobin, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, NLR neutrophil lymphocyte ration, IL-6 interleukin-6, PD-1 Programmed death-1, Tim-3 T cell immunoglobulin mucin-3, Treg Regulatory T cell, MDSC Myeloid-derived suppressor cell